Our history

Our business idea is to help people with chronic conditions and illnesses by using a patented treatment method that is neither surgical nor drug-based. The treatment is called Kinetic Oscillation Stimulation and is abbreviated K.O.S.

Today, we focus on chronic nasal congestion (rhinitis) which affects about 1.3 percent of the world's population, and partly on chronic migraines that affect 1.4-2.2 percent of the population with severe and frequent headaches.

International establishment

K.O.S is a product system for neurostimulation therapy with long-term effects, which modulates the autonomic nervous system functions. The rhinitis treatment is CE-certified and is sold in the EU. The migraine treatment is in a clinical trial phase, but was CE marked in May 2021 based on interim analysis data - and therefore currently under market introduction.

We want to establish our technology in the international market for neuromodulation. We sell our product system and our treatments through distributors to clinics and hospitals, who in turn treat the patients.

Listed on Nasdaq First North Growth Market

Today, the company has three employees, supported by a handful of expert consultants with extensive overall experience in medical technology product development, international market establishment, and clinical study activities. The business is entirely focused on sales in a few selected markets and the implementation of the two ongoing studies.

Chordate Medical AB, the Group's operating company, is a wholly owned subsidiary of Chordate Medical Holding AB (Publ), was listed on Nordic Growth Market-SME on March 8, 2017 and is since February 15, 2022, traded on Nasdaq First North Growth Market.

The company is based in Kista, outside Stockholm.

  • ...
  • ...
  • ...
  • ...
  • Interim analysis of the migraine study reports a positive indication
  • Italian and Nordic distributors invest in the company
  • The migraine study is expanded with four clinics in Finland
  • The basic patent is granted in the EU
  • Sales in Italy become commercially established
  • Distributor agreements are signed for Finland, Italy, Israel and the UK
  • The production of the electronics unit is outsourced to a subcontractor
  • First patient is included in the migraine study
  • Fixed costs are reduced
  • First patient is included in the rhinitis study
  • Joint Venture company with Nanos Medical is formed in Shanghai
  • The company is listed on NGM SME
  • All eight patent applications in China are approved
  • VINNOVA grants support of SEK 2 million for planned migraine study
  • Study of K.O.S.’ effect on heart rate variability (HRV) published in Annals of Noninvasive Electrocardiology
  • Distributor agreements are signed for the Danish and Norwegian markets
  • Own treatment clinic is opened in Kista
  • A letter of intent is signed with Nanos Medical on Joint Venture
  • Study (conducted in 2013) for chronic nasal congestion with 207 patients is published in the journal Acta Otolaryngologica
  • Distributor agreements are signed for markets in the Middle East and the UK
  • The company begins sales activities in Sweden and the search for distributors in the Nordic and UK
  • Study (conducted in 2008) published in Acta Otolaryngologica
  • Migraine study (conducted in 2013) published in Headache
  • Second-generation product system is CE marked
  • First migraine study with 36 patients is initiated
  • The second study for chronic nasal congestion with 207 patients begins at six clinics in Sweden
  • Additional patent applications are filed
  • The first ENT clinic starts using KOS treatment
  • First employees start
  • ISO 13485 and MDD certification are obtained
  • First product system is CE marked
  • Additional patent applications are filed
  • First external capital is obtained from an investor
  • First study for chronic nasal congestion with 71 patients at Karolinska Institute
  • Basic patent granted in Sweden
  • The subsidiary Chordate AB is founded by Professor Jan-Erik Juto, ENT surgeon at Karolinska in Huddinge, together with Fredrik Juto

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.


Contact us

The information is handled according to our  privacy policy.